Literature DB >> 33412211

TRIM proteins in lung cancer: Mechanisms, biomarkers and therapeutic targets.

Weihua Zhan1, Song Zhang2.   

Abstract

The tripartite motif (TRIM) family is defined by the presence of a Really Interesting New Gene (RING) domain, one or two B-box motifs and a coiled-coil region. TRIM proteins play key roles in many biological processes, including innate immunity, tumorigenesis, cell differentiation and ontogenetic development. Alterations in TRIM gene and protein levels frequently emerge in a wide range of tumors and affect tumor progression. As canonical E3 ubiquitin ligases, TRIM proteins participate in ubiquitin-dependent proteolysis of prominent components of the p53, NF-κB and PI3K/AKT signaling pathways. The occurrence of ubiquitylation events induced by TRIM proteins sustains internal balance between tumor suppressive and tumor promoting genes. In this review, we summarized the diverse mechanism of TRIM proteins responsible for the most common malignancy, lung cancer. Furthermore, we also discussed recent progress in both the diagnosis and therapeutics of tumors contributed by TRIM proteins.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarker; Lung cancer; TRIM proteins; Therapeutics; Ubiquitylation

Year:  2021        PMID: 33412211     DOI: 10.1016/j.lfs.2020.118985

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  10 in total

1.  Tripartite motif 52 (TRIM52) promotes proliferation, migration, and regulation of colon cancer cells associated with the NF-κB signaling pathway.

Authors:  Yanjiao Guo; Yiming Zhou; Xiaodong Gu; Jianbin Xiang
Journal:  J Gastrointest Oncol       Date:  2022-06

Review 2.  The role of PI3K/AKT signaling pathway in gallbladder carcinoma.

Authors:  Zeyu Wu; Xiao Yu; Shuijun Zhang; Yuting He; Wenzhi Guo
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

3.  TRIM24 is an insulin-responsive regulator of P-bodies.

Authors:  Wen Wei; Qiaoli Chen; Minjun Liu; Yang Sheng; Qian OuYang; Weikuan Feng; Xinyu Yang; Longfei Ding; Shu Su; Jingzi Zhang; Lei Fang; Antonio Vidal-Puig; Hong-Yu Wang; Shuai Chen
Journal:  Nat Commun       Date:  2022-07-08       Impact factor: 17.694

4.  [TRIM59 regulates invasion and migration of nasopharyngeal carcinoma cells by targeted modulation of PPM1B].

Authors:  W Wang; L Zhou; Z Sun; J Wu; Y Cui
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-07-20

5.  E3 ligase TRIM15 facilitates non-small cell lung cancer progression through mediating Keap1-Nrf2 signaling pathway.

Authors:  Manman Liang; Lijing Wang; Zhengui Sun; Xingwu Chen; Hanli Wang; Lilong Qin; Wenying Zhao; Biao Geng
Journal:  Cell Commun Signal       Date:  2022-05-09       Impact factor: 7.525

6.  Identification of TRIM56 as a Potential Biomarker for Lung Adenocarcinoma.

Authors:  Kun Lu; Yingli Sui; Lin Fu
Journal:  Cancer Manag Res       Date:  2021-03-04       Impact factor: 3.989

7.  A Novel Gene Signature of Tripartite Motif Family for Predicting the Prognosis in Kidney Renal Clear Cell Carcinoma and Its Association With Immune Cell Infiltration.

Authors:  Di Zheng; Yunlong Zhang; Yuqi Xia; Fan Cheng
Journal:  Front Oncol       Date:  2022-03-17       Impact factor: 6.244

Review 8.  Tripartite motif family proteins in inflammatory bowel disease: Mechanisms and potential for interventions.

Authors:  Rirong Chen; Yizhe Tie; Jinyu Lu; Li Li; Zhirong Zeng; Minhu Chen; Shenghong Zhang
Journal:  Cell Prolif       Date:  2022-04-04       Impact factor: 8.755

Review 9.  The roles and targeting options of TRIM family proteins in tumor.

Authors:  Yuxin Zhang; Wenzhou Zhang; Lufeng Zheng; Qianqian Guo
Journal:  Front Pharmacol       Date:  2022-09-30       Impact factor: 5.988

Review 10.  Potential of E3 Ubiquitin Ligases in Cancer Immunity: Opportunities and Challenges.

Authors:  Peng Ye; Xiaoxia Chi; Jong-Ho Cha; Shahang Luo; Guanghui Yang; Xiuwen Yan; Wen-Hao Yang
Journal:  Cells       Date:  2021-11-25       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.